All In Biotech

Drug Trial Radar · NCT06895031

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Mar 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.

Conditions

  • Solid Tumor
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)

Interventions

  • JYP0015Drug

    JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: 21 days
  2. Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEsTime frame: Up to 3 years
  3. Overall Response Rate (ORR)Time frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.